Literature DB >> 15467754

E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma.

Tsuyoshi Saito1, Yoshinao Oda, Ken-ichi Kawaguchi, Keishi Sugimachi, Hidetaka Yamamoto, Naomi Tateishi, Kazuhiro Tanaka, Shuichi Matsuda, Yukihide Iwamoto, Marc Ladanyi, Masazumi Tsuneyoshi.   

Abstract

We have recently reported frequent E-cadherin gene mutations in synovial sarcoma (SS), suggesting mutational inactivation of E-cadherin as a potential mechanism of spindle cell morphology in SS, a spindle cell sarcoma that shows areas of glandular epithelial differentiaton in some cases (biphasic SS) and only pure spindle cell morphology in most cases (monophasic SS). However, the mechanism of downregulation of E-cadherin in SS remains unknown. To further address this issue, we analysed the mechanisms of E-cadherin silencing in 40 SS. Genetic and epigenetic changes in the E-cadherin gene, and the expression level of its transcriptional repressor Snail were examined by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP), methylation-specific PCR, and real-time quantitative PCR, respectively. Expression of E-cadherin was examined by RT-PCR and immunohistochemistry. We also examined ELF3, a transcription factor associated with epithelial differentiation in SS in a previous cDNA microarray, by RT-PCR. E-cadherin and ELF3 transcripts were detected, respectively, in 27/40 (67.5%) and in 25/40 (62.5%) of SS, and these epithelial-related genes were almost always coexpressed. Hypermethylation of the promoter of the E-cadherin gene was detected in five cases (12.5%) in SS; however, E-cadherin was silenced at mRNA level in only one of the five cases. E-cadherin missense mutations were observed in five cases (12.5%) of SS. In SS, all five cases with E-cadherin missense mutations had the SYT-SSX1 fusion and were monophasic tumors, suggesting a relationship between the SYT-SSX fusion type and E-cadherin missense mutation (P=0.07). E-cadherin mRNA expression in SS was associated with reduced Snail expression level (P=0.03). E-cadherin membranous expression was observed in 14/40 (35.0%) of SS, and was also correlated with SYT-SSX1 fusion type and biphasic histology. ELF3 was confirmed to be more highly expressed in biphasic than monophasic SS by real-time quantitative PCR. These results suggest that in SS the loss of E-cadherin expression occurs either by Snail trans-repression or by inactivating mutations. Thus, E-cadherin downregulation is associated with the loss or absence of glandular epithelial differentiation in certain SS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467754     DOI: 10.1038/sj.onc.1207960

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer.

Authors:  Q Cao; J Yu; S M Dhanasekaran; J H Kim; R-S Mani; S A Tomlins; R Mehra; B Laxman; X Cao; J Yu; C G Kleer; S Varambally; A M Chinnaiyan
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

2.  Epithelial-mesenchymal transition transcription factors control pluripotent adult stem cell migration in vivo in planarians.

Authors:  Prasad Abnave; Ellen Aboukhatwa; Nobuyoshi Kosaka; James Thompson; Mark A Hill; A Aziz Aboobaker
Journal:  Development       Date:  2017-09-11       Impact factor: 6.868

3.  GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition.

Authors:  Wei Yan; Qing Jackie Cao; Richard B Arenas; Brooke Bentley; Rong Shao
Journal:  J Biol Chem       Date:  2010-02-26       Impact factor: 5.157

4.  Tissue microarray profiling of primary and xenotransplanted synovial sarcomas demonstrates the immunophenotypic similarities existing between SYT-SSX fusion gene confirmed, biphasic, and monophasic fibrous variants.

Authors:  Manish Mani Subramaniam; Samuel Navarro; Antonio Pellin; Jose Antonio López-Guerrero; Carmen Carda; Jose Antonio Heredia Alvaro; Pau Lluís Gozalbo Sabater; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2006-09-07       Impact factor: 4.064

5.  The correlation between morphology and the expression of TGF-β signaling pathway proteins and epithelial-mesenchymal transition-related proteins in synovial sarcomas.

Authors:  Yan Qi; Cui-Cui Wang; Yong-Lai He; Hong Zou; Chun-Xia Liu; Li-Juan Pang; Jian-Ming Hu; Jin-Fang Jiang; Wen-Jie Zhang; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

6.  Snail plays an oncogenic role in glioblastoma by promoting epithelial mesenchymal transition.

Authors:  Jae Kyung Myung; Seung Ah Choi; Seung-Ki Kim; Kyu-Chang Wang; Sung-Hye Park
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

7.  Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2'-deoxycytidine against synovial sarcoma cell lines.

Authors:  Kunihiko Numoto; Aki Yoshida; Shinsuke Sugihara; Toshiyuki Kunisada; Yuki Morimoto; Yasushi Yoneda; Yasuko Fujita; Keiichiro Nishida; Mamoru Ouchida; Toshifumi Ozaki
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

Review 8.  The SYT-SSX fusion protein and histological epithelial differentiation in synovial sarcoma: relationship with extracellular matrix remodeling.

Authors:  Tsuyoshi Saito
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

9.  Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR.

Authors:  Dongsheng Wang; Ling Su; Donghai Huang; Hongzheng Zhang; Dong M Shin; Zhuo G Chen
Journal:  Mol Cancer       Date:  2011-09-22       Impact factor: 27.401

10.  Next generation sequencing in synovial sarcoma reveals novel gene mutations.

Authors:  Myrella Vlenterie; Melissa H S Hillebrandt-Roeffen; Uta E Flucke; Patricia J T A Groenen; Bastiaan B J Tops; Eveline J Kamping; Rolph Pfundt; Diederik R H de Bruijn; Ad H M Geurts van Kessel; Han J H J M van Krieken; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers
Journal:  Oncotarget       Date:  2015-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.